Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The spironolactone renaissance.

S A Doggrell1, L Brown

  • 1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s_doggrell@yahoo.com

Expert Opinion on Investigational Drugs
|April 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health surveillance of Gulf War I veterans exposed to depleted uranium: updating the cohort.

Health physics·2007
Same author

Challenges and opportunities in processing muscle sympathetic nerve activity with wavelet denoising techniques: detecting single action potentials in multiunit sympathetic nerve recordings in humans.

Autonomic neuroscience : basic & clinical·2007
Same author

The impact of introducing a care pathway for the treatment of minor paediatrics burns.

Journal of wound care·2007
Same author

Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes.

Antiviral research·2006
Same author

Widespread neonatal brain damage following calcium channel blockade.

Developmental neuroscience·2006
Same author

Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2006

Spironolactone, initially a diuretic, now shows significant benefits in heart failure by reducing mortality and hospitalizations. It also demonstrates potential in treating other conditions like portal hypertension and certain hormonal imbalances.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Spironolactone was traditionally used as an aldosterone antagonist for hyperaldosteronism and as a diuretic.
  • Emerging research revealed spironolactone's direct cardiac and vascular effects, challenging its kidney-centric view.

Purpose of the Study:

  • To investigate the multifaceted therapeutic potential of spironolactone beyond its diuretic properties.
  • To evaluate the efficacy of spironolactone in managing heart failure and other aldosterone-related conditions.

Main Methods:

  • Clinical trials, including the Randomized Aldactone Evaluation Study (RALES), were conducted to assess spironolactone's impact on heart failure patients.
  • Experimental studies examined spironolactone's effects on cardiac fibrosis, vascular function, and hormonal activity.

Related Experiment Videos

Main Results:

  • The RALES trial demonstrated a 30% reduction in mortality risk for heart failure patients treated with spironolactone.
  • Spironolactone was shown to reduce hospitalizations, improve heart failure symptoms, decrease cardiac and vascular collagen turnover, and enhance endothelial function.
  • Experimental data indicated spironolactone's ability to reduce vascular fibrosis, inhibit angiogenesis, and decrease vascular tone.

Conclusions:

  • Spironolactone offers significant survival benefits and symptomatic improvement in heart failure, likely through its direct cardiovascular actions.
  • Spironolactone shows promise in treating conditions such as left ventricular hypertrophy, portal hypertension, cirrhosis, and certain androgen-related disorders.